(-)-Indolactam V is a PKC activator (Kis: 3.36 nM, 1.03 μM for η-CRD2 , γ-CRD2). (-)-Indolactam V also has the Kds are 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B). It has antitumor activity.

(-)-Indolactam V is a PKC activator (Kis: 3.36 nM, 1.03 μM for η-CRD2 , γ-CRD2). (-)-Indolactam V also has the Kds are 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B). It has antitumor activity.

(-)-Inpea HCl is a bioactive chemical.

(-)-Inpea HCl is a bioactive chemical.

Prenatal exposure to Integerrimine N-oxide induces maternal toxicity, impairment of maternal care and delayed in physical and behavioral development of the offspring. Doses of Integerrimine N-oxide here employed did not produce marked immunotoxic effects.

Prenatal exposure to Integerrimine N-oxide induces maternal toxicity, impairment of maternal care and delayed in physical and behavioral development of the offspring. Doses of Integerrimine N-oxide here employed did not produce marked immunotoxic effects.

Irofulven is an agent of DNA-damaging and antitumor. It is used for the treatment of advanced solid tumors, including prostate, ovarian, and pancreatic cancers.

Irofulven is an agent of DNA-damaging and antitumor. It is used for the treatment of advanced solid tumors, including prostate, ovarian, and pancreatic cancers.